Stock Performance and Market Context
On 25 Feb 2026, Lupin Ltd. recorded its highest price in the last 52 weeks at Rs.2270.4, marking a significant achievement for the company’s shares. The stock has been on a three-day consecutive gain streak, delivering a cumulative return of 2% during this period. Today’s price movement was in line with the Pharmaceuticals & Biotechnology sector, with a modest day change of 0.62%. The stock traded within a narrow range of Rs.15.75, indicating steady investor confidence and controlled volatility.
Lupin’s current price comfortably exceeds its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong technical foundation underpinning the rally. This upward trajectory is further supported by the broader market environment, where the Sensex advanced by 0.79%, closing at 82,874.89 points. Although the Sensex remains 3.96% shy of its own 52-week high of 86,159.02, Lupin’s outperformance relative to the benchmark is notable.
Comparative Returns and Sector Positioning
Over the past year, Lupin Ltd. has delivered a total return of 19.53%, significantly outperforming the Sensex’s 11.07% gain over the same period. This outperformance highlights the company’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector. The stock’s 52-week low was Rs.1774, illustrating a substantial appreciation of approximately 28% from its lowest point in the last year.
Within its sector, Lupin maintains a strong position, supported by a favourable Mojo Score of 78.0 and a current Mojo Grade of Buy, upgraded from Strong Buy on 16 Feb 2026. The company’s market capitalisation grade stands at 2, reflecting its mid-cap status and solid market presence.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Financial Strength and Growth Metrics
Lupin Ltd.’s financial profile supports its market performance. The company maintains a low average Debt to Equity ratio of 0.10 times, indicating prudent leverage management. Net sales have grown at an annualised rate of 11.42%, while operating profit margins stand at a healthy 33.60%, reflecting operational efficiency and strong cost controls.
Recent quarterly results have been positive for three consecutive quarters, with the latest quarter reporting a Profit Before Tax (PBT) excluding other income of Rs.1,833.91 crores, representing a 43.6% increase compared to the previous four-quarter average. Net sales for the quarter reached a record Rs.7,167.52 crores, underscoring robust demand and effective execution.
The company’s Return on Capital Employed (ROCE) for the half-year period is an impressive 22.22%, while Return on Equity (ROE) stands at 22%, indicating strong capital efficiency and shareholder value creation. Lupin’s Price to Book Value ratio is 5.2, which, despite being elevated, remains at a discount relative to its peers’ historical valuations.
Profitability and Valuation Insights
Over the past year, Lupin’s profits have surged by 73.5%, a remarkable growth rate that outpaces its share price appreciation of 19.53%. This disparity is reflected in a low PEG ratio of 0.3, suggesting that earnings growth is not fully priced into the stock. Institutional investors hold a significant 47.08% stake in Lupin, indicating confidence from entities with extensive analytical resources.
MarketsMojo ranks Lupin among the top 1% of all 4,000 stocks analysed, placing it 12th among mid-cap companies and 50th across the entire market. This ranking reflects the company’s consistent financial performance, quality metrics, and market standing.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Consistent Returns and Market Outperformance
Lupin Ltd. has demonstrated consistent returns over the last three years, outperforming the BSE500 index in each annual period. The stock’s 19.53% return in the past year further cements its status as a reliable performer within the mid-cap segment. This consistency is underpinned by strong fundamentals, disciplined capital allocation, and a focus on sustainable growth.
The company’s ability to maintain positive quarterly results and deliver expanding profit margins has contributed to its rising share price and the recent 52-week high. Lupin’s position within the Pharmaceuticals & Biotechnology sector remains robust, supported by favourable industry dynamics and its strategic initiatives.
Market and Technical Indicators
Technically, Lupin’s share price is well supported by its moving averages, trading above all key averages from short to long term. This technical strength complements the fundamental backdrop, providing a solid base for the current price levels. The narrow trading range observed today suggests a consolidation phase following the recent gains, which may help stabilise the stock price.
Meanwhile, the broader market’s positive momentum, led by mega-cap stocks, has created a conducive environment for Lupin’s share price appreciation. The Sensex’s current positioning, with the 50-day moving average above the 200-day moving average despite trading slightly below the 50DMA, indicates a cautiously optimistic market sentiment.
Summary
Lupin Ltd.’s achievement of a new 52-week high at Rs.2270.4 is a testament to its strong financial health, consistent earnings growth, and favourable market positioning. The stock’s outperformance relative to the Sensex and its sector peers highlights its resilience and momentum. Supported by solid fundamentals, attractive valuation metrics, and positive technical indicators, Lupin continues to be a noteworthy stock within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
